Memorandum of Understanding with Spire Healthcare

EDX Medical Group PLC

16 June 2025

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

16 June 2025

EDX Medical Group plc

AQSE: EDX

("EDX Medical" or the "Group" or "Company")

EDX MEDICAL SIGNS MEMORANDUM OF UNDERSTANDING

WITH SPIRE HEALTHCARE GROUP

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular disease and infectious diseases, announces today it has signed a memorandum of understanding with Spire Healthcare Group plc (LSE: SPI), a leading independent healthcare group in the UK.

Under the terms of the memorandum of understanding, EDX Medical and Spire Healthcare will explore opportunities to utilise new diagnostic products and patient testing services. This will include:

·   Promoting each other's existing and future clinical products and services.

• Establishing innovative patient referral and treatment pathways with the objective of cost-effectively improving patient outcomes.
• Developing joint healthcare and wellbeing propositions based on improved understanding of patient biology, disease risk and personalised treatments.

·   Providing services to support the delivery of world class independent healthcare in the United Kingdom.

Professor Sir Chris Evans, founder and chief scientific officer of EDX Medical, commented: "Spire Healthcare is an outstanding healthcare leader and we at EDX Medical are delighted to sign this agreement which paves the way for us to work together to further improve the delivery of innovative diagnostics and class-leading personalised medicine for patients. Relationships with leading hospital groups and clinics are an important element of our strategy to develop and supply the most advanced tests and supporting services available to treat major diseases."

Dr Mike Hudson, CEO, EDX Medical, commented: "We are excited to enter this new initiative with Spire Healthcare which promises to unlock important benefits for Spire's patients by providing their doctors with early access to advanced clinical diagnostic tools, enabling the delivery of world class personalised medicine."

Justin Ash, CEO, Spire Healthcare, said: "We have developed an excellent relationship with EDX Medical and are delighted to collaborate more closely to offer first option on and early access to new, innovative diagnostic products and patient testing services. Working in partnership will enable us to offer more personalised prevention support, treatment and care for people across a range of cancers, cardiovascular and other conditions."

The Board of directors of EDX Medical plc accepts responsibility for this announcement.

ENDS

Contacts

EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer)	[phone]
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	[phone]
Media House International
Ramsay Smith Gary McQueen	[phone] [e-mail] + 44 (0)7834 694609 [e-mail]
IFC Advisory (Investor Relations)
Tim Metcalfe Graham Herring	[phone]

Notes for Editors:

About EDX Medical Group plc

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com

About Spire Healthcare

Spire Healthcare is a leading independent healthcare group in the United Kingdom, running 38 hospitals and over 50 clinics, medical centres and consulting rooms across England, Wales and Scotland. It operates a network of private GPs and provides occupational health services to over 800 corporate clients.

Working in partnership with over 8,740 experienced consultants, Spire Healthcare delivered tailored, personalised care to over 1.3 million inpatients, outpatients and daycase patients, and occupational health programme clients, in 2024, and is the leading private provider, by volume, of knee and hip operations in the United Kingdom. It also delivers a range of private and NHS mental health, musculoskeletal and dermatological services under the Vita Health Group brand.

Spire Healthcare's well-located and scalable hospitals have delivered successful and award-winning outcomes, positioning the group well with patients, consultants, the NHS, GPs and Private Medical Insurance ('PMI') providers. 98% of Spire Healthcare's inspected locations are rated 'Good,' 'Outstanding' or the equivalent by health inspectors in England, Wales and Scotland.

Spire Healthcare is listed on the London Stock Exchange and is a member of the FTSE 250.

www.spirehealthcare.com

 

END